FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia

The US Food and Drug Administration has approved zanubrutinib for use in the treatment of adult patients with a rare form of non-Hodgkin lymphoma.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news